Anixa Mpro inhibitor

Anixa Mpro inhibitor is an undisclosed **preclinical small-molecule antiviral program** being developed by **Anixa Biosciences** in partnership with **MolGenie** for the treatment of **COVID-19**. The program comprises orally intended, room temperature-stable compounds designed to inhibit the **SARS-CoV-2 main protease**, also known as **Mpro** or **3CL protease**, an essential viral enzyme required for coronavirus polyprotein processing and replication. According to the provided context, the compounds were identified using artificial intelligence and showed early in vitro activity that was reported to be potentially more potent than nirmatrelvir in Mpro inhibition, but no specific clinical candidate name, active ingredient, or commercial brand has been publicly disclosed.

Other names

Anixa Mpro inhibitorAnixa main protease inhibitorAnixa SARS-CoV-2 Mpro inhibitor